Neoplasms

All Conditions

Adenocarcinoma

Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Antineoplastic Agents

All Drugs and Chemicals

Paclitaxel

Albumin-Bound Paclitaxel

Tubulin Modulators

Antimitotic Agents

cadonilimab combined +paclitaxel (albumin-bound)

1. In the safe induction phase6 subjects will receive cadonilimab (10mg/kg, Q3W, intravenous infusion, up to 2 years) and paclitaxel (albumin-bound type)(125 mg/m2,Days1, 8,Q3w, intravenous infusion, up to 8 cycles).
2. If the safety and tolerability are good, and the initial efficacy signal is observed, the extended enrollment phase will enter the extended enrollment phase of drug administration and the safety introduction phase

qian dong

jingdong zhang

Cadonilimab combined with paclitaxel (albumin-bound) treat advanced gastric adenocarcinoma or esophagogastric junction adenocarcinoma with PD-(L)1 inhibitors resistance

An open, multicenter, Phase II study of cadonilimab combined with paclitaxel (albumin-bound) in the treatment of advanced gastric adenocarcinoma or esophagogastric junction adenocarcinoma that has failed prior treatment with PD-(L)1 inhibitors

This is a single-arm, open, multicenter clinical study to evaluate the efficacy and safety of cadonilimab in combination with paclitaxel (albumin-bound type) as a second-line treatment for advanced gastric adenocarcinoma or esophagogastric junction adenocarcinoma The study included a screening period (no more than 28 days after the subject signed the informed consent letter to the first dose) treatment period (receiving the appropriate treatment regimen until the disease progression and toxicity of intolerable withdrawal of the informed consent letter and death or the end of the study, whichever occurred first) and follow-up period (including safety follow-up and survival follow-up).

Cadonilimab+ Paclitaxel (Albumin-bound) Treat Advanced Gastric Adenocarcinoma With PD-(L)1 Inhibitors Resistance

An Open, Multicenter, Phase II Study of Cadonilimab Combined With Paclitaxel (Albumin-bound) in the Treatment of Advanced Gastric Adenocarcinoma or Esophagogastric Junction Adenocarcinoma With PD-(L)1 Inhibitors Resistance

6-month progression-free survival assessed by RECIST v1.1

Incidence and severity of adverse events (AES) with clinically significant unusual

Spots Global Cancer Trial Database for Cadonilimab+ Paclitaxel (Albumin-bound) Treat Advanced Gastric Adenocarcinoma With PD-(L)1 Inhibitors Resistance

Trial Identification

Conditions

Interventions

Study Description

Keywords

Eligibility

Locations

Contact Details

Useful links and downloads for this trial